ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

stapokibart

Also written as “CM310”, “Stapokibart” and “Stapokibart injection”.

Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Nasal Polyps · Asthma, led by 3 companies.

Drug pageStapokibart: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 17, 202229 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciencesits history only246 open or runningphase 3since Feb 17, 2022Mar 12, 2021Feb 2027phase 3 · NCT07106372
Chengdu Kangnuoxing Biopharma,Inc.33 open or runningphase 3since Sep 30, 2025Sep 30, 2025Dec 2026phase 3 · NCT07678931
CSPC Pharmaceutical Groupits history only22 open or runningphase 3since Feb 27, 2023Feb 27, 2023Apr 29, 2032phase 3 · NCT06547333

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chengdu Kangnuoxing Biopharma,Inc. only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2023Named stapokibartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, CM310
  2. Sep 30, 2025First study: phase 3 study in Pemphigoid, BullousFirst studyNCT07210554 · 200 planned · China
  3. May 21, 2026Phase 2 study in Rhinitis, Allergic, SeasonalNCT07617324 · 15 planned · China
  4. Jun 25, 2026Phase 3 study in Rhinitis, Allergic, SeasonalNCT07678931 · 136 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalNCT07678931
  2. Mar 27, 2028Primary completion: phase 3 study in Pemphigoid, BullousNCT07210554

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Chengdu Kangnuoxing Biopharma,Inc. leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07678931Rhinitis, Allergic, Seasonal · China3RecruitingDec 2026136
NCT07617324Rhinitis, Allergic, Seasonal · China2Not yet recruitingOct 202615
NCT07210554Pemphigoid, Bullous · China3Not yet recruitingMar 27, 2028200

How it is read

Names in the registry

  • “CM310”, 22 entries
  • “Stapokibart”, 2 entries
  • “Stapokibart injection”, 2 entries
  • “Stapokibatrt”, 2 entries
  • “Stapokibart Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.